Medtronic Resolute Onyx DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe - Seite 3

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

BioFreedom is a trademark or registered trademark of Biosensors International Group, Ltd.

-end-

¹ Windecker S. Stent Selection for 1-3 Month DAPT: Current Evidence Ongoing Studies. Presented at TCT 2018; San Diego, CA.

² Costa F, et al. Lancet. 2017;389:1025-1034.

³ Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents:  Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.

⁴ Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. 2020; 382:1208-1218.doi: 10.1056/NEJMoa1910021.

Allison Kyriagis
Public Relations
[phone]

Ryan Weispfenning
Investor Relations
[phone]